Chai Discovery Triples Its Valuation to $3.8 Billion in Seven Months
Chai Discovery, the two-year-old AI drug design startup founded by former OpenAI and Meta researchers, closed a $400 million Series C at a $3.8 billion valuation, tripling its price tag in seven months. The round, led by Index Ventures, includes repeat backing from OpenAI itself. Its models now design antibodies for Eli Lilly, Pfizer and Novartis.